Unity Biotechnology

Unity Biotechnology is a biotechnology company developing drugs and treatments to diminish negative health effects associated with aging that is headquartered in Brisbane, California and was founded in 2009 by Nathaniel David, Jan Van Deursen, Judith Campisi, and Daohong Zhou.

Funding

Convertible note

On May 4, 2009 Unity Biotechnology received a convertible note worth $250,000.

Venture round

On July 15, 2013 Unity Biotechnology completed a venture capital fundraising round with $2 million in funding from undisclosed investors.

Series B

On October 27, 2016 Unity Biotechnology completed their series B funding round with $116 million in funding from Bezos Expeditions (lead investor), WuXi AppTec, Venrock, Mayo Clinic, Ballie Gifford, and ARCH Venture Partners. On August 17, 2017 Unity Biotechnologies closed an additional series B funding round with $35 million in funding from several new investors including: INVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, and Pivotal Alpha Limited.

Series C

On March 19, 2018 Unity Biotechnology completed their series C funding round with $55 million in funding from EcoR1 Capital (lead investor), Altitude Life Science Ventures (lead investor), 6 Dimensional Capital (lead investor), Venrock,

The Longevity Fund, Pivotal Alpha Limited, Partner Fund Management, Invus, Founders Fund, Fidelity Management and Research Company, Chestnut Street Ventures, and Ballie Gifford.